Motor deficits that associate with changes in β -amyloid in Parkinson's disease

Author/Contributor:

Halliday, Glenda

Publication details:

Journal of Neurology, Neurosurgery and Psychiatry

v. 84

Chapter No. 5

pp. 475-476

0022-3050 (ISSN)

Publication Date:

2012

Publisher DOI:

<http://dx.doi.org/10.1136/jnnp-2012-304177>

License:

<https://creativecommons.org/licenses/by-nc-nd/3.0/au/>

Link to license to see what you are allowed to do with this resource.

Downloaded from <http://hdl.handle.net/1959.4/53620> in <https://unsworks.unsw.edu.au> on 2023-04-26

Motor deficits that associate with changes in β -amyloid in Parkinson's disease

Professor Glenda Halliday, Neuroscience Research Australia, Randwick, NSW 2031, Australia, phone: +61-2-93991704, fax: +61-2-93991105, email: g.halliday@neura.edu.au

β -Amyloid ($A\beta$) deposition in the brain is one of the main pathologic hallmarks of Alzheimer's disease (AD) with dominant gene mutations significantly increasing the amount of this protein in the brain and heralding an early onset of dementia¹. Deposition of $A\beta$ in the brain identified by PET imaging is closely associated with decreased CSF levels of the protein, tools that are now used clinically to assist with the diagnosis of AD.

There is considerable ongoing debate regarding the overlap of AD pathology and its contribution to Parkinson's disease (PD), but there are few studies that have assessed CSF levels of AD proteins for correlations with motor impairments in sporadic PD. The study by Alves and colleagues in this issue of JNNP assesses 99 *de novo* PD patients with either tremor-dominant (PD-TD) or postural instability/gait disorders (PD-PIGD) for relationships to CSF levels of $A\beta$ proteins². It is deficient in assessing the other major AD protein tau, but their findings of reduced CSF Abeta levels in the *de novo* PD-PIGD group compared with PD-TD and controls is significant. The CSF Abeta levels correlated with the severity of PIGD and lower limb bradykinesia but not other motor features. The study was well controlled for age of onset, MRI white matter hyperintensities and cognition, and could therefore show a clear biological difference underpinning this type of motor impairment in PD. It will be important to know if the correlate extends to CSF tau levels as well, and therefore typical AD rather than $A\beta$ dysfunction alone.

The association of $A\beta$ proteins to motor dysfunction in PD has not been previously considered, although recent studies using preclinical LRRK2 mutation carriers considerably strengthen the concept of early $A\beta$ changes in PD. In particular, reduced striatal dopamine function strongly correlates with reduced CSF $A\beta$ proteins³ rather than CSF α -synuclein levels⁴ in these preclinical LRRK2 cases. In sporadic PD, many studies have shown correlations between reduced CSF $A\beta$ and cognitive impairment and more rapid cognitive decline⁵⁻⁸, particularly with deficits in verbal fluency which may have a motor component. Interestingly, patients with PD dementia often have no $A\beta$ on PET imaging despite cortical atrophy and hypometabolism⁹, suggesting that significant compact $A\beta$ deposition may not underlie these deficits, findings consistent with pathological studies¹⁰⁻¹¹. However, other pathological studies assessing AD proteins in addition to α -synuclein have identified non PD-TD patients as having higher grades of α -synuclein pathology, more cortical $A\beta$ and cerebral amyloid, and dementia at end-stage, with similar levels of pathology observed in patients with the dominant dementia syndrome of dementia with Lewy bodies¹²⁻¹⁵. In pathological studies, there is evidence that additional $A\beta$ deposition in the brain increases the rate of disease progression¹³⁻¹⁶, consistent with the increased progression observed in the PD-PIGD subtype¹⁷. It is difficult to reconcile these end-stage pathologies with the *de novo* data in the Alves et al paper², but it is clear that, rather than just concentrating on the role $A\beta$ plays in dementia in PD, the biological role $A\beta$ may play in motor circuits to produce the motor phenotypes of PD also needs further assessment. Importantly, the early biological differences identified by Alves and colleagues² could be used to monitor effective treatments for these deficits in the future.

Advancing knowledge on the biology underlying the clinical heterogeneity in patients with PD can not be underestimated. While patients with PD-PIGD are known to differ from those patients with PD-TD in several clinical factors, they also have more marked dopamine deficiency and greater cortical impairments than other motor subtypes of PD¹⁷. Whether any

of these differences also relate to their A β dysfunction awaits further studies. However, it has recently been shown that PD-PIGD have increased susceptibility for motor impulsivity¹⁸ and that non PD-TD patients have greater visual processing impairments¹⁹. Such neuropsychological findings are likely to directly contribute to falls risk and could also relate to A β dysfunction in PD. In addition, myocardial sympathetic degeneration correlates with hypokinesia in non PD-TD patients²⁰, a non A β pathology that may also contribute to the PD-PIGD subtype. While more work is now required, the study by Alves and colleagues in this issue highlights an important piece of the biological puzzle concerning why patients with PD may have such diverse clinical phenotypes.

References

1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 2012;367(9):795-804.
2. Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, et al. Amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2012;in press.
3. Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. *Neurology* 2012;78(1):55-61.
4. Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. *Neurobiol Aging* 2012;33(4):836 e5-7.
5. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. *Parkinsonism Relat Disord* 2011;17(1):61-4.
6. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. *Neurology* 2010;75(12):1055-61.
7. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valdeoriola F, Munoz E, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. *Mov Disord* 2009;24(15):2203-10.
8. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, et al. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. *Dement Geriatr Cogn Disord* 2006;22(3):200-8.
9. Jokinen P, Scheinin N, Aalto S, Nagren K, Savisto N, Parkkola R, et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. *Parkinsonism Relat Disord* 2010;16(10):666-70.
10. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. *J Neural Transm* 2011;118(5):713-9.
11. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol* 2012.
12. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. *Brain* 2009;132(Pt 11):2947-57.
13. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? *Brain* 2011;134(Pt 5):1493-505.
14. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. *Acta Neuropathol* 2008;115(4):409-15.
15. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. *Acta Neuropathol* 2011;122(2):187-204.
16. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. *Ann N Y Acad Sci* 2010;1184:188-95.
17. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? *J Neurol Neurosurg Psychiatry* 2012.
18. Wylie SA, van den Wildenberg W, Ridderinkhof KR, Claassen DO, Wooten GF, Manning CA. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2012.
19. Seichepine DR, Neargarder S, Miller IN, Riedel TM, Gilmore GC, Cronin-Golomb A. Relation of Parkinson's disease subtypes to visual activities of daily living. *J Int Neuropsychol Soc* 2011;17(5):841-52.

20. Chung EJ, Kim EG, Kim MS, Bae SK, Seog DH, Oh SJ, et al. Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson's disease. *J Clin Neurosci* 2011;18(7):922-5.